Last reviewed · How we verify
clonazepam and paroxetine
Clonazepam enhances inhibitory GABA signaling in the central nervous system while paroxetine inhibits serotonin reuptake, together reducing anxiety and depressive symptoms.
Clonazepam enhances inhibitory GABA signaling in the central nervous system while paroxetine inhibits serotonin reuptake, together reducing anxiety and depressive symptoms. Used for Anxiety disorders, Panic disorder, Major depressive disorder with anxiety.
At a glance
| Generic name | clonazepam and paroxetine |
|---|---|
| Sponsor | National Institute of Mental Health (NIMH) |
| Drug class | Benzodiazepine + SSRI combination |
| Target | GABA-A receptor (clonazepam); serotonin transporter (paroxetine) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Mental Health |
| Phase | FDA-approved |
Mechanism of action
Clonazepam is a benzodiazepine that potentiates GABA-A receptor activity, increasing chloride influx and neuronal hyperpolarization to produce anxiolytic and sedative effects. Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that blocks the serotonin transporter, increasing synaptic serotonin availability to improve mood and reduce anxiety. This combination targets both GABAergic and serotonergic systems for synergistic anxiolytic and antidepressant effects.
Approved indications
- Anxiety disorders
- Panic disorder
- Major depressive disorder with anxiety
- Obsessive-compulsive disorder
Common side effects
- Sedation/drowsiness
- Dizziness
- Nausea
- Headache
- Tremor
- Dependence/withdrawal risk (clonazepam)
- Sexual dysfunction (paroxetine)
Key clinical trials
- Efficacy of Hydroxyzine for Patients With Panic Disorder (PHASE4)
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- Long Term Treatment of Panic Disorder With Clonazepam or Paroxetine (PHASE4)
- Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression (PHASE4)
- Clonazepam and Paroxetine for Rapid Treatment of Post-Traumatic Stress Disorder (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- clonazepam and paroxetine CI brief — competitive landscape report
- clonazepam and paroxetine updates RSS · CI watch RSS
- National Institute of Mental Health (NIMH) portfolio CI